Monte Rosa Therapeutics (GLUE) Price & Analysis

Compare

362 Followers

GLUE Stock Chart & Stats

$23.99

-$0.20(-2.99%)

At close: Jan 08 4:00 PM EST

$23.99

-$0.20(-2.99%)

Day’s Range― - ―

52-Week Range$3.50 - $25.77

Previous CloseN/A

Volume283.19K

Average Volume (3M)2.08M

Market Cap

$1.83B

Enterprise Value$442.39M

Total Cash (Recent Filing)$391.26M

Total Debt (Recent Filing)$40.17M

Price to Earnings (P/E)78.8

Beta1.58

Next Earnings

Mar 12, 2026

EPS Estimate

-0.33

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.33

Shares Outstanding76,242,760

10 Day Avg. Volume3,974,880

30 Day Avg. Volume2,079,409

Financial Highlights & Ratios

PEG Ratio0.11

Price to Book (P/B)2.30

Price to Sales (P/S)6.78

P/FCF Ratio13.50

Enterprise Value/Market Cap0.24

Enterprise Value/Revenue2.44

Enterprise Value/Gross Profit2.47

Enterprise Value/Ebitda22.62

Forecast

1Y Price Target

$33.80

Price Target Upside40.89% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Biomarker EfficacyAnalyst highlights that MRT-8102 produced strong reductions in hsCRP and lowered inflammatory cytokines IL-6 and IL-1β, providing early proof of concept for cardiovascular benefit.

Safety Profile And Trial AdvancementAnalyst notes a favorable safety profile reported in early studies with no observed serious adverse events and that MRT-8102 is progressing into Part 3 of the Phase I program to refine safety and biomarker understanding.

Strategic Partnerships And Funding SupportAnalyst points to the Novartis collaboration and broader partner interest as validation of the platform and as support for funded Phase 2 execution with potential milestone and revenue upside.

Bears Say

Financing And Market RiskAnalyst warns that high short interest combined with substantial cash burn increases financing risk and can amplify stock volatility if additional funding is needed.

Potential Hepatotoxicity SignalAnalyst flags a serious liver enzyme elevation in a trial participant, creating uncertainty about possible drug-related hepatotoxicity that requires close monitoring.

Study Size And Design LimitationsAnalyst cautions that the small sample size and uncontrolled nature of the early trials limit confidence in efficacy signals and hinder assessment of broader clinical benefit.

Monte Rosa Therapeutics News

Monte Rosa Therapeutics price target raised to $37 from $27.50 at Piper Sandler

Piper Sandler raised the firm’s price target on Monte Rosa Therapeutics (GLUE) to $37 from $27.50 and keeps...

1d ago

GLUE

Monte Rosa Therapeutics 11.125M share Secondary priced at $24.00

The deal size was increased to $300M in common stock and pre-funded warrants from $200M. Jefferies, TD Cowen...

6d ago

GLUE

Monte Rosa Therapeutics announces $200M common stock offering

Monte Rosa Therapeutics (GLUE) announced that it has commenced an underwritten public offering of $200M of shares of...

8d ago

GLUE

Monte Rosa Therapeutics price target raised to $31 from $22 at Jefferies

Jefferies raised the firm’s price target on Monte Rosa Therapeutics (GLUE) to $31 from $22 and keeps a...

8d ago

GLUE

Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!

TipRanks offers all of the hottest stock market news for Wednesday in its daily wrap-up. ...

8d ago

AAL

AMD

Midday Fly By: Warner Bros. urges holders to reject Paramount bid

The major averages were mixed near noon following two days of gains as investors take profits and shift...

8d ago

Monte Rosa data position MRT-8102 ‘favorably,’ says LifeSci Capital

After Monte Rosa announced an update with data from the placebo-controlled Phase 1 trial testing their NEK7-targeted molecular...

8d ago

GLUE

Monte Rosa Therapeutics price target raised to $37 from $26 at Wedbush

Wedbush raised the firm’s price target on Monte Rosa Therapeutics (GLUE) to $37 from $26 and keeps an...

8d ago

GLUE

Here’s Why Monte Rosa Therapeutics Stock (GLUE) Rocketed Today

Monte Rosa Therapeutics stock soared on Wednesday after the company posted strong results from a clinical trial. ...

8d ago

GLUE

Monte Rosa Therapeutics announces Phase 1 data of MRT-8102

Monte Rosa Therapeutics (GLUE) announced positive interim data from an ongoing Phase 1 clinical study evaluating MRT-8102, a...

8d ago

GLUE

Monte Rosa Therapeutics Prices $300 Million Public Offering

Monte Rosa Therapeutics ( ($GLUE) ) just unveiled an announcement. On January 8, 2026, Monte Rosa Therapeutics priced...

6d ago

GLUE

Monte Rosa Therapeutics Ends Current ATM Equity Program

An update from Monte Rosa Therapeutics ( ($GLUE) ) is now available. Effective January 7, 2026, Monte Rosa...

8d ago

GLUE

Monte Rosa Therapeutics: Early MRT-8102 hsCRP Data Underscore Differentiated NLRP3 Opportunity and Attractive Risk-Reward Supporting Buy Rating

LifeSci Capital analyst Oliver McCammon has maintained their bullish stance on GLUE stock, giving a Buy rating on...

8d ago

GLUE

Monte Rosa reports positive Phase 1 data for MRT-8102

An update from Monte Rosa Therapeutics ( ($GLUE) ) is now available. On January 7, 2026, Monte Rosa...

8d ago

GLUE

GLUE FAQ

What was Monte Rosa Therapeutics’s price range in the past 12 months?

Monte Rosa Therapeutics lowest stock price was $3.50 and its highest was $25.77 in the past 12 months.

What is Monte Rosa Therapeutics’s market cap?

Monte Rosa Therapeutics’s market cap is $1.83B.

When is Monte Rosa Therapeutics’s upcoming earnings report date?

Monte Rosa Therapeutics’s upcoming earnings report date is Mar 12, 2026 which is in 56 days.

How were Monte Rosa Therapeutics’s earnings last quarter?

Monte Rosa Therapeutics released its earnings results on Nov 06, 2025. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.366 by $0.036.

Is Monte Rosa Therapeutics overvalued?

According to Wall Street analysts Monte Rosa Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Monte Rosa Therapeutics pay dividends?

Monte Rosa Therapeutics does not currently pay dividends.

What is Monte Rosa Therapeutics’s EPS estimate?

Monte Rosa Therapeutics’s EPS estimate is -0.33.

How many shares outstanding does Monte Rosa Therapeutics have?

Monte Rosa Therapeutics has 76,242,760 shares outstanding.

What happened to Monte Rosa Therapeutics’s price movement after its last earnings report?

Monte Rosa Therapeutics reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.366. Following the earnings report the stock price went up 5.686%.

Which hedge fund is a major shareholder of Monte Rosa Therapeutics?

Currently, no hedge funds are holding shares in GLUE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Monte Rosa Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

9.28%

Trailing 12-Months

Asset Growth

45.94%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Monte Rosa Therapeutics

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Monte Rosa Therapeutics (GLUE) Earnings & Revenues

Historic Earnings Reports

GLUE Stock 12 Month Forecast

Average Price Target

$33.80

▲(40.89% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","38":"$38","11.75":"$11.75","20.5":"$20.5","29.25":"$29.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":37,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$37.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$33.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$30.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,11.75,20.5,29.25,38],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.68,17.32,18.96,20.6,22.240000000000002,23.880000000000003,25.52,27.16,28.8,30.44,32.08,33.72,35.36,{"y":37,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.68,17.073846153846155,18.467692307692307,19.861538461538462,21.255384615384614,22.64923076923077,24.043076923076924,25.436923076923076,26.830769230769228,28.224615384615383,29.61846153846154,31.01230769230769,32.40615384615384,{"y":33.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.68,16.78153846153846,17.883076923076924,18.984615384615385,20.086153846153845,21.18769230769231,22.28923076923077,23.39076923076923,24.49230769230769,25.593846153846155,26.695384615384615,27.79692307692308,28.89846153846154,{"y":30,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.9,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.22,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.94,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.5,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.43,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.61,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.79,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.92,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.85,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.78,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.68,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >